Literature DB >> 16015383

The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107.

N von Bubnoff, S H P Gorantla, R K Kancha, F Lordick, C Peschel, J Duyster.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16015383     DOI： 10.1038/sj.leu.2403887

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  17 in total

1.  Mastocytosis: the great masquerader.

Authors:  James S W Kong; Suzanne Teuber; Rosemary Hallett; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2006-02       Impact factor: 8.667

Review 2.  Management of endocrine disease: Secondary osteoporosis: pathophysiology and management.

Authors:  Faryal Mirza; Ernesto Canalis
Journal:  Eur J Endocrinol       Date:  2015-05-13       Impact factor: 6.664

Review 3.  Oncogenic pathways of AML1-ETO in acute myeloid leukemia: multifaceted manipulation of marrow maturation.

Authors:  Kamaleldin E Elagib; Adam N Goldfarb
Journal:  Cancer Lett       Date:  2006-11-27       Impact factor: 8.679

4.  The role of Lin28b in myeloid and mast cell differentiation and mast cell malignancy.

Authors:  L D Wang; T N Rao; R G Rowe; P T Nguyen; J L Sullivan; D S Pearson; S Doulatov; L Wu; R C Lindsley; H Zhu; D J DeAngelo; G Q Daley; A J Wagers
Journal:  Leukemia       Date:  2015-02-06       Impact factor: 11.528

Review 5.  Mastocytosis: update on pharmacotherapy and future directions.

Authors:  Juan Carlos Cardet; Cem Akin; Min Jung Lee
Journal:  Expert Opin Pharmacother       Date:  2013-10       Impact factor: 3.889

6.  Systemic mastocytosis associated with t(8;21)(q22;q22) acute myeloid leukemia.

Authors:  Sheeja T Pullarkat; Vinod Pullarkat; Steven H Kroft; Carla S Wilson; Arshad N Ahsanuddin; Karen P Mann; Maung Thein; Wayne W Grody; Russell K Brynes
Journal:  J Hematop       Date:  2009-02-10       Impact factor: 0.196

7.  Genetic and pharmacologic evidence implicating the p85 alpha, but not p85 beta, regulatory subunit of PI3K and Rac2 GTPase in regulating oncogenic KIT-induced transformation in acute myeloid leukemia and systemic mastocytosis.

Authors:  Veerendra Munugalavadla; Emily C Sims; Jovencio Borneo; Rebecca J Chan; Reuben Kapur
Journal:  Blood       Date:  2007-05-04       Impact factor: 22.113

Review 8.  Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts.

Authors:  Luke F Peterson; Anita Boyapati; Eun-Young Ahn; Joseph R Biggs; Akiko Joo Okumura; Miao-Chia Lo; Ming Yan; Dong-Er Zhang
Journal:  Blood       Date:  2007-04-05       Impact factor: 22.113

Review 9.  AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL.

Authors:  E Weisberg; P Manley; J Mestan; S Cowan-Jacob; A Ray; J D Griffin
Journal:  Br J Cancer       Date:  2006-05-23       Impact factor: 7.640

Review 10.  Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression.

Authors:  Srdan Verstovsek
Journal:  Eur J Haematol       Date:  2013-02       Impact factor: 2.997
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.